IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

dc.contributor.author
Thiagarajan, Divya
dc.contributor.author
Oparina, Nina
dc.contributor.author
Lundström, Susanna
dc.contributor.author
Zubarev, Roman
dc.contributor.author
Sun, Jitong
dc.contributor.author
PRECISESADS Clinical Consortium
dc.contributor.author
Alarcón Riquelme, Marta
dc.contributor.author
Frostegård, Johan
dc.contributor.author
Cervera i Segura, Ricard, 1960-
dc.date.issued
2021-05-18T09:43:35Z
dc.date.issued
2021-05-18T09:43:35Z
dc.date.issued
2020-07-03
dc.date.issued
2021-05-18T09:43:35Z
dc.identifier
2045-2322
dc.identifier
https://hdl.handle.net/2445/177351
dc.identifier
708149
dc.identifier
32620913
dc.description.abstract
IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren's syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.
dc.format
13 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Nature Publishing Group
dc.relation
Reproducció del document publicat a: https://doi.org/10.1038/s41598-020-66981-z
dc.relation
Scientific Reports, 2020, vol. 10
dc.relation
https://doi.org/10.1038/s41598-020-66981-z
dc.rights
cc-by (c) Thiagarajan, Divya et al., 2020
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Artritis reumatoide
dc.subject
Immunoglobulines
dc.subject
Rheumatoid arthritis
dc.subject
Immunoglobulins
dc.title
IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)